Literature DB >> 2900644

Failure of dopexamine to maintain haemodynamic improvement in patients with chronic heart failure.

J J Murphy1, J R Hampton.   

Abstract

Ten patients with chronic heart failure were given a continuous infusion of dopexamine after an initial stage of dose titration. On the dose selected the cardiac index initially rose by 56%, as a result of an increase in both heart rate and stroke volume index. Systemic vascular resistance fell by 34% and the mean arterial pressure did not change. Within 18 hours of the start of the continuous infusion, however, all the variables except heart rate had returned to preinfusion values. Nine of the 10 patients were withdrawn from the 48 hour study, six because of haemodynamic deterioration and two because of side effects. If the premature loss of therapeutic effect reflects an intrinsic property of this agent, dopexamine may be of limited clinical value.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2900644      PMCID: PMC1216513          DOI: 10.1136/hrt.60.1.45

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  17 in total

1.  Role of beta-adrenergic receptors in catecholamine-induced desensitization of adenylate cyclase in human astrocytoma cells.

Authors:  G L Johnson; B B Wolfe; T K Harden; P B Molinoff; J P Perkins
Journal:  J Biol Chem       Date:  1978-03-10       Impact factor: 5.157

2.  The cardiovascular effects of the continuous infusion of dobutamine in patients with severe cardiac failure.

Authors:  C V Leier; J Webel; C A Bush
Journal:  Circulation       Date:  1977-09       Impact factor: 29.690

Review 3.  Dopamine--clinical uses of an endogenous catecholamine.

Authors:  L I Goldberg
Journal:  N Engl J Med       Date:  1974-10-03       Impact factor: 91.245

4.  Cardiac pumping capability and prognosis in heart failure.

Authors:  L B Tan
Journal:  Lancet       Date:  1986-12-13       Impact factor: 79.321

Review 5.  Combined vasodilator and inotropic therapy of heart failure: experimental and clinical concepts.

Authors:  R R Miller; A R Palomo; T A Brandon; C J Hartley; M A Quinones
Journal:  Am Heart J       Date:  1981-09       Impact factor: 4.749

6.  Tolerance to dobutamine after a 72 hour continuous infusion.

Authors:  D A Unverferth; M Blanford; R E Kates; C V Leier
Journal:  Am J Med       Date:  1980-08       Impact factor: 4.965

7.  Dopexamine: a novel agonist at peripheral dopamine receptors and beta 2-adrenoceptors.

Authors:  R A Brown; J Dixon; J B Farmer; J C Hall; R G Humphries; F Ince; S E O'Connor; W T Simpson; G W Smith
Journal:  Br J Pharmacol       Date:  1985-07       Impact factor: 8.739

8.  Acute haemodynamic and metabolic effects of dopexamine, a new dopaminergic receptor agonist, in patients with chronic heart failure.

Authors:  J R Dawson; D S Thompson; M Signy; S M Juul; P Turnbull; B S Jenkins; M M Webb-Peploe
Journal:  Br Heart J       Date:  1985-09

9.  Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol.

Authors:  W S Colucci; R W Alexander; G H Williams; R E Rude; B L Holman; M A Konstam; J Wynne; G H Mudge; E Braunwald
Journal:  N Engl J Med       Date:  1981-07-23       Impact factor: 91.245

10.  The effects of dopexamine on the cardiovascular system of the dog.

Authors:  R A Brown; J B Farmer; J C Hall; R G Humphries; S E O'Connor; G W Smith
Journal:  Br J Pharmacol       Date:  1985-07       Impact factor: 8.739

View more
  4 in total

Review 1.  Dopexamine in congestive heart failure: how do the pharmacological activities translate into the clinical situation?

Authors:  T Meinertz; H Drexler; H Just
Journal:  Basic Res Cardiol       Date:  1989       Impact factor: 17.165

2.  The effects of dopexamine, a new dopamine analogue, on platelet function in stress.

Authors:  D Wagaine-Twabwe; T J Hendra; C C Smith; J S Yudkin
Journal:  Br J Clin Pharmacol       Date:  1990-07       Impact factor: 4.335

3.  Effects of chronic intravenous infusions of dopexamine and isoprenaline to rats on D1-, beta 1- and beta 2-receptor-mediated responses.

Authors:  S W Martin; K J Broadley
Journal:  Br J Pharmacol       Date:  1994-06       Impact factor: 8.739

Review 4.  Dopexamine hydrochloride. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in acute cardiac insufficiency.

Authors:  A Fitton; P Benfield
Journal:  Drugs       Date:  1990-02       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.